The (Cost-) Effectiveness of Mindfulness-training and Cognitive Behavioural Therapy in Adolescents and Young Adults With Deliberate Self Harm (DSH)

November 5, 2009 updated by: Leiden University Medical Center

Background:

In recent years, there has been a marked rise in the frequency of young people engaging in Deliberate Self-Harm (DSH). DSH refers to all kinds of self-harming behaviour, with and without suicidal intent. Early identification and treatment of persons who engaged in DSH is important because every episode of DSH increases the risk of future episodes and, eventually, suicide. A number of comprehensive treatment programs have been developed and proven to be effective in reducing DSH in adults. Especially the modification of inadequate emotion regulation strategies seems to be essential in the prevention of future episodes of DSH. The first short-term results of a Dutch time-limited and structured individual cognitive-behavioral treatment (CBT) for DSH in adolescents and young adults also showed positive effects on repetition of DSH and associated problems.

Objective:

To study the effects and costs of the total individual CBT package and one of the components of the total CBT treatment package (i.e. mindfulness training) in a group format compared to Treatment-as-Usual (TAU) on the short and long term.

Design:

Multi-center randomized controlled clinical trial with repeated measurements at baseline (M0),and posttreatment (M6)), 12 (M12) and 18 months (M18) after baseline.

Procedure:

Young persons aged 15-35 who recently have engaged in DSH and have been referred to the Leiden University Medical Centre, the mental health centre Rivierduinen or the University Medical Centre St. Radboud following an act of DSH will be invited to participate. Persons reporting severe psychiatric disorders requiring intensive inpatient treatment or serious cognitive impairments will be excluded.

Interventions:

Participants are randomly allocated to CBT, Mindfulness-Based Cognitive Therapy(MBCT) or Treatment-as-Usual (TAU). The CBT treatment consists of up to 12 weekly sessions of individual treatment mainly consisting of emotion regulations skills, cognitive restructuring, and behavioural skills training. The MBCT training consists of 8 2-hour sessions in a group format within a three months time frame.

Outcome measures:

The same outcome measures to assess the clinical effects of treatment as in the previous study will be used (repetition of DSH, depression (BDI-II), anxiety (SCL-90), self-concept(RSC-Q), and suicide cognitions (SCS)) allowing a historical comparison of treatment effectiveness across both randomized clinical trials. In addition at all assessments health-related quality of life, use of medical resources and loss of productivity will be assessed (EuroQol, VAS and TTO). In addition,problems in emotion regulation (an important risk mechanism for repetition of DSH) will be assessed before and after treatment.

Economic evaluation:

Differences in societal costs (intervention, other (health) care and productivity)will be compared to differences in the frequency of DSH and quality adjusted life years (EuroQol, VAS and TTO).

Data-analysis/power:

Based on our previous study at least a medium effect of treatment on repetition of DSH may be expected. Assuming a medium effect of one of the treatments compared to TAU (delta =.75) and an attrition rate of about 20 %, at least 42 patients per study arm are needed to detect a minimal clinical relevant difference in repetition of DSH with a power of 80% and alpha set at .05.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

84

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Gelderland
    • Zuid-Holland
      • Leiden, Zuid-Holland, Netherlands
        • Recruiting
        • Leiden University Medical Centre
        • Contact:
      • Leiden, Zuid-Holland, Netherlands
        • Recruiting
        • Rivierduinen Mental Health Centre
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 35 years (ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Recently engaged in an act of DSH including overdose of medication, ingestion of chemical substances and self-inflicted injuries according to the definition which is used in the WHO/Euro Multicentre Study on parasuicide:"An act with non-fatal outcome in which an individual deliberately initiates a non-habitual behavior, that without intervention from other will cause self-harm, or deliberately ingests a substance in excess of the prescribed or generally recognized dosage, and which is aimed at realizing changes that the person desires via the actual or expected physical consequences"(Platt et al., 1992).
  • Aged between 15 and 35
  • Living in the region of Leiden or Nijmegen

Exclusion Criteria:

  • Severe psychiatric disorder or substance abuse requiring intensive inpatient treatment
  • Serious cognitive impairments
  • Not be able to converse in Dutch

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: 1
Cognitive Behavioural Treatment
Brief cognitive behavioral therapy (12 sessions)
EXPERIMENTAL: 2
Mindfulness Based Cognitive Therapy-training
9 sessions MBCT in a group-format (up to 8 persons)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Repetition of DSH, measured by the suicide attempt and self injury interview (SASII). Frequency, method and other characteristics of deliberate self-harm and suicide attempts are assessed.
Time Frame: M0, M6, M12, M18
M0, M6, M12, M18

Secondary Outcome Measures

Outcome Measure
Time Frame
depression, as measured by the Beck depression Inventory II
Time Frame: M0, M6, M12, M18
M0, M6, M12, M18
Anxiety, as measured by the symptom checklist '90
Time Frame: M0, M6, M12, M18
M0, M6, M12, M18
Hostility, as measured by the symptom checklist '90
Time Frame: M0, M6, M12, M18
M0, M6, M12, M18
Self-concept, as measured by the Robson self-concept questionnaire
Time Frame: M0, M6, M12, M18
M0, M6, M12, M18
Suicidal cognitions, as measured by the suicidal cognitions scale
Time Frame: M0, M6, M12, M18
M0, M6, M12, M18
QALYs, assessed by the EQ5D
Time Frame: M0, M6, M12, M18
M0, M6, M12, M18
COSTS, assessed by a 6-monthly diary
Time Frame: M0 - M6, M6 - M12, M12 - M18
M0 - M6, M6 - M12, M12 - M18
Problem-solving skills, as measured by the Means Ends Problem-Solving Test
Time Frame: M0, M6
M0, M6
Experimental avoidance, as measured by the Acceptance and Action Questionnaire
Time Frame: M0, M6
M0, M6
difficulties in emotion-regulation, as measured by the difficulties in emotion regulation scale
Time Frame: M0, M6
M0, M6
general tendency to ruminate, as measured by the Ruminative Response Scale
Time Frame: M0, M6
M0, M6
mindfulness skills, as measured by the Five Facet Mindfulness Questionnaire
Time Frame: M0, M6
M0, M6
pathological dissociation, as measured by the dissociative experiences scale - taxon
Time Frame: M0, M6
M0, M6
Autobiographical memory, assessed by the autobiographical memory task
Time Frame: M0, M6
M0, M6
worrying, as measured by the Penn State Worry Questionnaire
Time Frame: M0 M6
M0 M6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Philip Spinhoven, Prof. dr., Leiden University, Institute for Psychological Research
  • Study Director: Arnold A.P. van Emmerik, Dr., Leiden University, Clinical Psychology Unit
  • Study Director: Anne E. van Giezen, Dr., Leiden University, Institute for Psychological Research, Clinical Psychology Unit
  • Study Chair: Anne E.M. Speckens, Prof. dr., Radboud University Medical Center
  • Principal Investigator: Suzanne de Klerk, MSc., Leiden University, Institute for Psychological Research, Clinical Psychology Unit

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2008

Primary Completion (ANTICIPATED)

November 1, 2010

Study Completion (ANTICIPATED)

October 1, 2012

Study Registration Dates

First Submitted

June 5, 2008

First Submitted That Met QC Criteria

June 9, 2008

First Posted (ESTIMATE)

June 10, 2008

Study Record Updates

Last Update Posted (ESTIMATE)

November 6, 2009

Last Update Submitted That Met QC Criteria

November 5, 2009

Last Verified

November 1, 2009

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe